Skip to main content
ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
1.990
-0.030 (-1.49%)
At close: Aug 13, 2025, 4:00 PM
1.970
-0.020 (-1.01%)
Pre-market: Aug 14, 2025, 9:13 AM EDT

ImmunoPrecise Antibodies Revenue

In the fiscal year ending April 30, 2025, ImmunoPrecise Antibodies had annual revenue of 24.52M CAD with 0.01% growth. ImmunoPrecise Antibodies had revenue of 6.98M in the quarter ending April 30, 2025, with 8.08% growth.

Revenue (ttm)
24.52M CAD
Revenue Growth
+0.01%
P/S Ratio
3.74
Revenue / Employee
240,392 CAD
Employees
102
Market Cap
91.85M USD

Revenue Chart

* This company reports financials in CAD.

History

Fiscal Year End Revenue Change Growth
Apr 30, 202524.52M2.00K0.01%
Apr 30, 202424.52M3.85M18.65%
Apr 30, 202320.67M1.30M6.72%
Apr 30, 202219.36M1.45M8.11%
Apr 30, 202117.91M3.85M27.42%
Apr 30, 2020 Pro Pro Pro
Apr 30, 2019 Pro Pro Pro
Apr 30, 2018 Pro Pro Pro
Apr 30, 2017 Pro Pro Pro
Apr 30, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 422.82B
Johnson & Johnson 90.63B
Merck & Co. 63.62B
AbbVie 58.33B
AstraZeneca 56.50B
Novartis AG 55.19B
Eli Lilly and Company 53.26B
Novo Nordisk 49.11B
Revenue Rankings

IPA News

More News